Karachi, Dec 28 : The final journey of former Pakistan Prime Minister Benaz
Panaji/New Delhi, Dec 28: Expressing sh
Shimla/New Delhi, Dec 27 : After winning nearly two-third majority in Gujarat earlier this week, the B
London, Dec 28 : The Conservatives in BritainHDFC Bank’s Q3 FY26 performance underscores a bank firmly transitioning from post-merger balance-sheet recalibration to a renewed phase of earnings momentum.
News in Focus
Tech Mahindra is entering a decisive phase of recovery after posting its strongest operational quarter in nearly three years.
Canara Bank, Bank of India, PNB, SBI, UCO Bank were among major gainers on Friday as public sectors banks were in focus.
ICICI Prudential Life Insurance delivered a quarter that reinforced its evolving investment narrative: moderate near-term growth, but structurally improving profitability.
Featured, India Business, Analyst View, Stock Markets, India, Infosys, Motilal Oswal, Technology Sector
Infosys has entered 2026 with early but credible signs of a discretionary demand revival, prompting Motilal Oswal Financial Services to reiterate its BUY rating on the stock.
ICICI Lombard’s Q3FY26 performance reflects a quarter of optical weakness driven by accounting mechanics and one-off costs, rather than a deterioration in business fundamentals.
Main Regional Stories
Featured, India Business, Analyst View, Deven Choksey, Finance Sector, India, JIO Financial Services
Jio Financial Services’ Q3FY26 performance marks a defining transition from Reliance-Group's new financial services venture to a maturing financial services major with operationally anchored earnings, a shift long awaited by institutional investor
In the Philippines, leisure has always been social first and scheduled second: a borrowed chair outside the gate, a basketball rolling across a barangay court, a song requested twice because everyone knows the chorus.
Featured, Analyst View, Stock Markets, India, Jubilant Pharmova, Pharmaceutical Sector, Ventura Securities
Ventura Securities has initiated coverage on Jubilant Pharmova Ltd with a "BUY" recommendation at the current market price of Rs 1,067, assigning a 24-month price target of Rs 1,557, representing a compelling 50% upside potential.
HDFC Asset Management Company delivered a resilient and earnings-accretive performance in Q3FY26, reinforcing its position as one of India’s most structurally sound asset managers.
